$KVUE News

Kenvue Benefits From Consumer Health Trends and Margin Expansion

Kenvue Increases Quarterly Cash Dividend

What Are Wall Street Analysts' Target Price for Kenvue Stock?

Kenvue Increases Quarterly Dividend By 1.2% To $0.21 Per Share

Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)

Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?

Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight

KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback

FDA Approves Kenvue’s TYLENOL With Naproxen, OTC Fixed-Dose Combination Of Acetaminophen And Naproxen Sodium

FDA Approves First Nonprescription Fixed-Dose Combination Of Acetaminophen, Naproxen Sodium For 12-Hour Pain Relief

Kenvue to Announce Second Quarter 2026 Results on August 6, 2026

What to Expect From Kenvue’s Q2 2026 Earnings Report

Barclays Maintains Equal-Weight on Kenvue, Raises Price Target to $19

UBS Maintains Neutral on Kenvue, Raises Price Target to $20

KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits

Kenvue (KVUE) Stock May Be A Bargain Despite The Acquisition Bid

Kenvue (KVUE) Faces A $48.7 Billion Kimberly Clark Deal And Big Portfolio Questions

Kenvue, Maker of Neutrogena(R), Aveeno(R), OGX(R), and Zyrtec(R), Beats 2025 Packaging Goal, Demonstrates Continued Progress With More Sustainable Innovation

Is Kenvue Stock Underperforming the S&P 500?

Kenvue Canada saves big on diesel costs with Fuel Transport EV pilot